The Impact of CYP2D6 Genotyping on Tamoxifen Treatment

被引:17
作者
Ferraldeschi, Roberta [1 ,2 ]
Newman, William G. [2 ]
机构
[1] Christie Hosp NHS Trust, Dept Med Oncol, Manchester M20 4BX, Lancs, England
[2] Univ Manchester, MAHSC, St Marys Hosp, Genet Med, Oxford Rd, Manchester M13 9WL, Lancs, England
关键词
tamoxifen; CYP2D6; genotyping; breast cancer;
D O I
10.3390/ph3041122
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Tamoxifen remains a cornerstone of treatment for patients with oestrogen-receptor-positive breast cancer. Tamoxifen efficacy depends on the biotransformation, predominantly via the cytochrome P450 2D6 (CYP2D6) isoform, to the active metabolite endoxifen. Both genetic and environmental (drug-induced) factors may alter CYP2D6 enzyme activity directly affecting the concentrations of active tamoxifen metabolites. Several studies suggest that germline genetic variants in CYP2D6 influence the clinical outcomes of patients treated with adjuvant tamoxifen. Here, we review the existing data relating CYP2D6 genotypes to tamoxifen efficacy.
引用
收藏
页码:1122 / 1138
页数:17
相关论文
共 63 条
[61]   The Tamoxifen Metabolite, Endoxifen, Is a Potent Antiestrogen that Targets Estrogen Receptor α for Degradation in Breast Cancer Cells [J].
Wu, Xianglin ;
Hawse, John R. ;
Subramaniam, Malayannan ;
Goetz, Matthew P. ;
Ingle, James N. ;
Spelsberg, Thomas C. .
CANCER RESEARCH, 2009, 69 (05) :1722-1727
[62]   Association between CYP2D6*10 genotype and survival of breast cancer patients receiving tamoxifen treatment [J].
Xu, Y. ;
Sun, Y. ;
Yao, L. ;
Shi, L. ;
Wu, Y. ;
Ouyang, T. ;
Li, J. ;
Wang, T. ;
Fan, Z. ;
Fan, T. ;
Lin, B. ;
He, L. ;
Li, P. ;
Xie, Y. .
ANNALS OF ONCOLOGY, 2008, 19 (08) :1423-1429
[63]   Functional pharmacogenetics/genomics of human cytochromes P450 involved in drug biotransformation [J].
Zanger, Ulrich M. ;
Turpeinen, Miia ;
Klein, Kathrin ;
Schwab, Matthias .
ANALYTICAL AND BIOANALYTICAL CHEMISTRY, 2008, 392 (06) :1093-1108